RBC maintains Medicis at outperform

Medicis Pharmaceutical Corp. was kept at outperform, above average risk, by RBC Capital Markets analyst Ken Trbovich on news that IMS data shows 7,136 Solodyn prescriptions for the week ended Sept. 15, an increase of 19%. Oral acne prescriptions continue on pace above RBC's estimates. The Medicis acne franchise is 86% from the comparable week last year. Solodyn, tracking at $135 million run-rate 12 weeks into its launch, could exceed a $175 million run-rate. Shares of the Scottsdale, Ariz.-based specialty pharmaceutical company were up 57 cents, or 1.90%, at $30.50. (NYSE: MRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.